We will just have to agree to disagree...you read it one way and I read it another. That sentence in that PR comes after they talk about Phase 2. So to me they are talking about the phase 2 biomarkers. This shouldn't be confidential like the Pfizer/Rhinat agreements. Intellect announced the deal and the drug being developed. So Intellect should be allowed to tell its shareholders if a milestone would be paid after a phase 1 trial is complete. They never announced they would receive a milestone after phase 1. I also find it odd that Viopharma conducted another phase 1 trial since Intellect already had done one. GLTY
I think Maza is required by law to report income/revenue via 10q even if there is a private agreement. They may have a non disclosure clause in their contract, but, revenue must be reported. Not sure about that. If yes, the milestone payment will eventually show up in the 10q.
I have not seen any public detailed contractual terms regarding Viropharma/Intellect & OX1.
News 
Market Data 
Discover 
